<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818245</url>
  </required_header>
  <id_info>
    <org_study_id>12152</org_study_id>
    <secondary_id>I2R-MC-BIDF</secondary_id>
    <nct_id>NCT01818245</nct_id>
  </id_info>
  <brief_title>A Study of LY2605541 in Healthy Participants and in the Elderly</brief_title>
  <official_title>Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will include 2 groups (cohorts) of participants:

      In Cohort A, this study will look at the amount of LY2605541 that is present in the body
      after it is injected in 3 different locations in the body of the same participant. At least
      16 days will pass between each injection.

      In Cohort B, the study will look at how the body absorbs, distributes, and disposes of
      LY2605541 in participants aged 65 and over.

      Participants may enroll in only one cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</measure>
    <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
    <description>AUC from time zero to infinity (AUC(0-∞)) of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</measure>
    <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
    <description>Cmax of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Elderly Participants (≥65 Years of Age) Versus Participants ≤55 Years of Age (Abdominal Injection)</measure>
    <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
    <description>AUC(0-∞) for LY2605541 was evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax): Elderly Participants (≥65 Years of Age) Versus Participants ≤55 Years of Age (Abdominal Injection)</measure>
    <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
    <description>Cmax of LY2605541 was evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Total Amount of Glucose Infused (Gtot): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</measure>
    <time_frame>Predose up to 24 hours post clamp procedure in all treatment periods</time_frame>
    <description>Gtot was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</measure>
    <time_frame>Predose up to 24 hours post clamp procedure in all treatment periods</time_frame>
    <description>Rmax was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2605541: Cohort A (Injection site: Abdomen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≤55 years of age will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541: Cohort A (Injection site: Upper Arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541: Cohort A (Injection site: Thigh)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2605541: Cohort B (Injection site: Abdomen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2605541</intervention_name>
    <arm_group_label>LY2605541: Cohort A (Injection site: Abdomen)</arm_group_label>
    <arm_group_label>LY2605541: Cohort A (Injection site: Thigh)</arm_group_label>
    <arm_group_label>LY2605541: Cohort A (Injection site: Upper Arm)</arm_group_label>
    <arm_group_label>LY2605541: Cohort B (Injection site: Abdomen)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cohort A: are overtly healthy male or female participants, as determined by medical
             history and physical examination, aged ≥18 to ≤55 years of age

          -  Cohort B: are male or female elderly (≥65 years of age) participants that are overtly
             healthy, or have stable, chronic medical conditions (including Type 2 Diabetes
             Mellitus [T2DM]) that, in the investigator's opinion, will not significantly alter the
             disposition of the drug, will not place the participant at increased risk by
             participating in the study, and will not interfere with interpretation of the data

          -  Male participants agree to use a reliable method of birth control during the study and
             for 3 months following the last dose of the investigational product

          -  Female participants are women of child-bearing potential who test negative for
             pregnancy at the time of screening based on a urine pregnancy test and agree to use a
             reliable method of birth control during the study and for 1 month following the last
             dose of the investigational product

          -  Female participants are post-menopausal women, or women not of child-bearing potential
             due to surgical sterilization (at least 3 months after surgical hysterectomy, or at
             least 3 months after bilateral oophorectomy or bilateral tubal ligation/occlusion with
             or without hysterectomy) confirmed by medical history, or menopause

          -  Have a body mass index (BMI) of 18.5 to 40 kilogram per meter square (kg/m^2),
             inclusive, at time of admission for Period 1

          -  Have given written informed consent approved by Lilly and the ethical review board
             (ERB) governing the site

        Exclusion Criteria:

          -  Are participants that intend to start a change in diet or lose weight during the
             study; participants will be expected to maintain their approximate current weight
             throughout the study

          -  Are excessive smokers (&gt;10 cigarettes per day); participants who smoke ≤10 cigarettes
             per day must be able to stop smoking while residing at the clinical research unit
             (CRU)

        Healthy Participants - Cohort A

          -  Have Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), or a fasting
             blood glucose (BG) &gt;110 milligrams per deciliter (mg/dL) (6.1 millimoles per liter
             [mmol/L]) with a glycated hemoglobin (HbA1c) of &gt;6.2%

          -  Intend to use over-the-counter medication within the 7 days or prescription medication
             within 14 days prior to dosing (apart from contraceptive medication, vitamin/mineral
             supplements, occasional paracetamol, thyroxine replacement therapy, and hormone
             replacement therapy). Antihypertensive and lipid lowering agents are permitted, but
             must have been administered at stable dose(s) for at least 1 month.

        Elderly Participants - Cohort B

          -  Have T1DM

          -  Are T2DM participants that require insulin treatment, or have a HbA1c of &gt;10%

          -  Have started new chronic medication(s) or changed the dose of an existing chronic
             medication &lt;1 month prior to dosing. Participants are permitted to continue ongoing
             chronic medications (for example antihypertensive agents, aspirin, non-steroidal
             anti-inflammatory drugs, lipid lowering agents, thyroxine, hormone replacement
             therapy, and/or oral anti-diabetic if participants have T2DM). Other stable chronic
             conditions may be permitted if deemed acceptable by the investigators and Lilly
             clinical pharmacologist or clinical research physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <results_first_submitted>March 17, 2018</results_first_submitted>
  <results_first_submitted_qc>March 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2018</results_first_posted>
  <last_update_submitted>March 17, 2018</last_update_submitted>
  <last_update_submitted_qc>March 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LY2605541: Cohort A (Participants ≤55 Years of Age)</title>
          <description>Participants ≤55 years of age were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 16-28 day washout.
Intervention A: participants ≤55 years of age received 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the abdominal wall on Day 1 of the treatment period.
Intervention B: participants ≤55 years of age received 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 of the treatment period.
Intervention C: participants ≤55 years of age received 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 of the treatment period.</description>
        </group>
        <group group_id="P2">
          <title>LY2605541: Cohort B (Participants ≥65 Years of Age)</title>
          <description>Participants ≥65 years of age received 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22">Participants didn't participate in separate interventions and received 1 dose of LY2605541 on Day 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (16-28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (16-28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention C</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>LY2605541: Cohort A (Participants ≤55 Years of Age)</title>
          <description>Participants ≤55 years of age were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 16-28 day washout.
Intervention A: participants ≤55 years of age received 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1 of the treatment period.
Intervention B: participants ≤55 years of age received 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 of the treatment period.
Intervention C: participants ≤55 years of age received 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 of the treatment period.</description>
        </group>
        <group group_id="B2">
          <title>LY2605541: Cohort B (Participants ≥65 Years of Age)</title>
          <description>Participants ≥65 years of age received 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="9.1"/>
                    <measurement group_id="B2" value="71.4" spread="6.3"/>
                    <measurement group_id="B3" value="51.7" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</title>
        <description>AUC from time zero to infinity (AUC(0-∞)) of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
        <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
        <population>Participants in Cohort A who received LY2605541 and had evaluable AUC(0-∞) data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2605541: Cohort A (Injection Site: Abdomen)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>LY2605541: Cohort A (Injection Site: Upper Arm)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O3">
            <title>LY2605541: Cohort A (Injection Site: Thigh)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</title>
          <description>AUC from time zero to infinity (AUC(0-∞)) of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
          <population>Participants in Cohort A who received LY2605541 and had evaluable AUC(0-∞) data.</population>
          <units>picomoles*hours/liter (pmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124000" spread="37"/>
                    <measurement group_id="O2" value="133000" spread="39"/>
                    <measurement group_id="O3" value="135000" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</title>
        <description>Cmax of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
        <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
        <population>Participants in Cohort A who received LY2605541 and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2605541: Cohort A (Injection Site: Abdomen)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>LY2605541: Cohort A (Injection Site: Upper Arm)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O3">
            <title>LY2605541: Cohort A (Injection Site: Thigh)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Observed Maximum Plasma Concentration (Cmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</title>
          <description>Cmax of LY2605541 was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
          <population>Participants in Cohort A who received LY2605541 and had evaluable Cmax data.</population>
          <units>picomoles/liter (pmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1839.17" spread="59"/>
                    <measurement group_id="O2" value="1700.68" spread="54"/>
                    <measurement group_id="O3" value="2027.99" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Elderly Participants (≥65 Years of Age) Versus Participants ≤55 Years of Age (Abdominal Injection)</title>
        <description>AUC(0-∞) for LY2605541 was evaluated.</description>
        <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
        <population>Participants in Cohort A and B who received LY2605541 in the abdomen and had evaluable AUC(0-∞) data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2605541: Cohort A (Injection Site: Abdomen)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>LY2605541: Cohort B (Injection Site: Abdomen)</title>
            <description>Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Elderly Participants (≥65 Years of Age) Versus Participants ≤55 Years of Age (Abdominal Injection)</title>
          <description>AUC(0-∞) for LY2605541 was evaluated.</description>
          <population>Participants in Cohort A and B who received LY2605541 in the abdomen and had evaluable AUC(0-∞) data.</population>
          <units>pmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124000" spread="37"/>
                    <measurement group_id="O2" value="134000" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Plasma Concentration (Cmax): Elderly Participants (≥65 Years of Age) Versus Participants ≤55 Years of Age (Abdominal Injection)</title>
        <description>Cmax of LY2605541 was evaluated.</description>
        <time_frame>Predose and 2, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, and 216 hours postdose</time_frame>
        <population>Participants in Cohort A and B who received LY2605541 in the abdomen and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2605541: Cohort A (Injection Site: Abdomen)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>LY2605541: Cohort B (Injection Site: Abdomen)</title>
            <description>Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Plasma Concentration (Cmax): Elderly Participants (≥65 Years of Age) Versus Participants ≤55 Years of Age (Abdominal Injection)</title>
          <description>Cmax of LY2605541 was evaluated.</description>
          <population>Participants in Cohort A and B who received LY2605541 in the abdomen and had evaluable Cmax data.</population>
          <units>pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1839.17" spread="59"/>
                    <measurement group_id="O2" value="1829.92" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Total Amount of Glucose Infused (Gtot): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</title>
        <description>Gtot was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
        <time_frame>Predose up to 24 hours post clamp procedure in all treatment periods</time_frame>
        <population>Participants in Cohort A who received LY2605541 and had evaluable Gtot data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2605541 - Cohort A (Injection Site: Abdomen)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>LY2605541: Cohort A (Injection Site: Upper Arm)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O3">
            <title>LY2605541: Cohort A (Injection Site: Thigh)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Total Amount of Glucose Infused (Gtot): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</title>
          <description>Gtot was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
          <population>Participants in Cohort A who received LY2605541 and had evaluable Gtot data.</population>
          <units>milligrams/kilograms (mg/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="674" spread="109"/>
                    <measurement group_id="O2" value="633" spread="102"/>
                    <measurement group_id="O3" value="454" spread="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</title>
        <description>Rmax was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
        <time_frame>Predose up to 24 hours post clamp procedure in all treatment periods</time_frame>
        <population>Participants in Cohort A who received LY2605541 and had evaluable Rmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2605541: Cohort A (Injection Site: Abdomen)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O2">
            <title>LY2605541: Cohort A (Injection Site: Upper Arm)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods.</description>
          </group>
          <group group_id="O3">
            <title>LY2605541: Cohort A (Injection Site: Thigh)</title>
            <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A)</title>
          <description>Rmax was evaluated across injection sites (abdominal wall, arm, and thigh).</description>
          <population>Participants in Cohort A who received LY2605541 and had evaluable Rmax data.</population>
          <units>milligrams/minute/kilogram (mg/min/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.944" spread="88"/>
                    <measurement group_id="O2" value="0.935" spread="83"/>
                    <measurement group_id="O3" value="0.738" spread="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY2605541: Cohort A (Injection Site: Abdomen)</title>
          <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods.</description>
        </group>
        <group group_id="E2">
          <title>LY2605541: Cohort A (Injection Site: Upper Arm)</title>
          <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods.</description>
        </group>
        <group group_id="E3">
          <title>LY2605541: Cohort A (Injection Site: Thigh)</title>
          <description>Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods.</description>
        </group>
        <group group_id="E4">
          <title>LY2605541: Cohort B (Injection Site: Abdomen)</title>
          <description>Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

